Targeted therapy

Jump to navigation Jump to search

WikiDoc Resources for Targeted therapy


Most recent articles on Targeted therapy

Most cited articles on Targeted therapy

Review articles on Targeted therapy

Articles on Targeted therapy in N Eng J Med, Lancet, BMJ


Powerpoint slides on Targeted therapy

Images of Targeted therapy

Photos of Targeted therapy

Podcasts & MP3s on Targeted therapy

Videos on Targeted therapy

Evidence Based Medicine

Cochrane Collaboration on Targeted therapy

Bandolier on Targeted therapy

TRIP on Targeted therapy

Clinical Trials

Ongoing Trials on Targeted therapy at Clinical

Trial results on Targeted therapy

Clinical Trials on Targeted therapy at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Targeted therapy

NICE Guidance on Targeted therapy


FDA on Targeted therapy

CDC on Targeted therapy


Books on Targeted therapy


Targeted therapy in the news

Be alerted to news on Targeted therapy

News trends on Targeted therapy


Blogs on Targeted therapy


Definitions of Targeted therapy

Patient Resources / Community

Patient resources on Targeted therapy

Discussion groups on Targeted therapy

Patient Handouts on Targeted therapy

Directions to Hospitals Treating Targeted therapy

Risk calculators and risk factors for Targeted therapy

Healthcare Provider Resources

Symptoms of Targeted therapy

Causes & Risk Factors for Targeted therapy

Diagnostic studies for Targeted therapy

Treatment of Targeted therapy

Continuing Medical Education (CME)

CME Programs on Targeted therapy


Targeted therapy en Espanol

Targeted therapy en Francais


Targeted therapy in the Marketplace

Patents on Targeted therapy

Experimental / Informatics

List of terms related to Targeted therapy


Targeted therapy is a type of medication which blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with rapidly dividing cells. Targeted cancer therapies may be more effective than current treatments and less harmful to normal cells.

The main categories of targeted therapy are small molecules and monoclonal antibodies.

Small molecules

Mechanism imatinib.jpg
  • Imatinib mesylate (Gleevec®, also known as STI–571) is approved for chronic myelogenous leukemia, gastrointestinal stromal tumor and some other types of cancer. Early clinical trials indicate that imatinib may be effective in treatment of dermatofibrosarcoma protuberans.
  • Gefitinib (Iressa®, also known as ZD1839), targets the epidermal growth factor receptor (EGFR) tyrosine kinase and is approved in the U.S. for non small cell lung cancer. EGFR is also overexpressed in the cells of other solid tumors, such as lung and breast cancers. This leads to inappropriate activation of the apoptotic Ras signal transduction cascade, eventually leading to uncontrolled cell proliferation.Gefitinib inhibits EGFR tyrosine kinase by binding to the adenosine triphosphate (ATP)-binding site of the enzyme. Thus the function of the EGFR tyrosine kinase in activating the Ras signal transduction cascade is inhibited; and malignant cells are inhibited.
  • Erlotinib (marketed as Tarceva). Erlotinib works through a similar mechanism as gefitinib. Erlotinib has been shown to increase survival in metastatic non small cell lung cancer when used as second line therapy. Because of this finding, erlotinib has replaced gefitinib in this setting.
  • Bortezomib (Velcade®) is an apoptosis-inducing drug that causes cancer cells to undergo cell death by interfering with proteins. It is approved in the U.S. to treat multiple myeloma that has not responded to other treatments.

Monoclonal antibodies

Main article: Monoclonal antibody therapy

Several are in development and a few have been licenced by the FDA. Examples of licenced monoclonal antibodies include:

Progress and future

Many oncologists believe that targeted therapies are the chemotherapy of the future. As solid tumor cancer continues to be viewed as a chronic condition, methods for long-term treatment, with less side-effects, continue to be investigated.

In the U.S., the National Cancer Institute's Molecular Targets Development Program (MTDP) to identify and evaluate molecular targets that may be candidates for drug development.

The next stage of targeted therapies will focus on finding which patients will respond to which targeted therapies. This is called the identification of "sub-populations". The route to identify these sub-populations is through biomarkers and surrogate endpoints.


See also

de:Gezielte Krebstherapie Template:WH Template:WikiDoc Sources